News & Views

ONS Virtual Conference Offers Live and On-Demand Content for Oncology Nurses

This September, the Oncology Nursing Society (ONS) will host the second annual ONS Bridge™, the premier virtual conference that connects oncology nurses to resources and education covering two themes: care coordination and updates in therapy.

Trending Topics

View All Topics

FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

U.S. Food and Drug Administration (FDA)

FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

Cancer research

Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

The Case of the Mysterious Myalgia

The Case of the Mysterious Myalgia

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

U.S. Food and Drug Administration (FDA)

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

Meet Your ONS Leader: Valerie Burger

Meet Your ONS Leader: Valerie Burger

Diagnose and Treat Hypercalcemia of Malignancy

Advanced Practice Nursing (APRN)

Diagnose and Treat Hypercalcemia of Malignancy

New Evidence-Based Practice Learning Library Now Available

New Evidence-Based Practice Learning Library Now Available

Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

Nurse Research AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

Oncology nurse researcher

Nurse Researcher AIMS to Increase Screening for Malnutrition and Reduce Bowel Dysfunction

The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

U.S. Food and Drug Administration (FDA)

FDA Approves Daratumumab and Hyaluronidase-Fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

Leadership, Goals, and Missions Drive ONS’s Work

Leadership, Goals, and Missions Drive ONS’s Work

FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

U.S. Food and Drug Administration (FDA)

FDA Grants Regular Approval to Enfortumab Vedotin-Ejfv for Locally Advanced or Metastatic Urothelial Cancer

Nursing Considerations for Ovarian Cancer Survivorship Care

Nursing Considerations for Ovarian Cancer Survivorship Care

Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

Genetics & genomics

Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

Clinical practice

Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

Treatment side effects

Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

Food for Thought: Prevent and Screen for Malnutrition in Patients with Cancer

Clinical practice

Food for Thought: Prevent and Screen for Malnutrition in Patients With Cancer

Nurses Are the Key to Achieving Health Equity

Nurses Are the Key to Achieving Health Equity

FDA Approves Asparaginase Erwinia Chrysanthemi for Leukemia and Lymphoma

U.S. Food and Drug Administration (FDA)

FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn for Leukemia and Lymphoma

Strong Social Relationships Strengthen and Sustain You

Nurse well-being

Strong Social Relationships Strengthen and Sustain You

Immunotherapy Extends Survival in Uveal Melanoma

Immunotherapy Extends Survival in Uveal Melanoma

Oncology Drug Reference Sheet: Tepotinib

Drug Reference Sheet

Oncology Drug Reference Sheet: Tepotinib

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

U.S. Food and Drug Administration (FDA)

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Cancer research

Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Conflict Engagement Helps Providers Focus on Care

Clinical practice

Conflict Engagement Helps Providers Focus on Care

When Grief Goes Beyond Burnout, Organizations Must Intervene

Grief & bereavement

When Grief Goes Beyond Burnout, Organizations Must Intervene

APRNs Are Essential in Survivorship Programs

Survivorship care plans

APRNs Are Essential in Survivorship Programs

Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care

Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care

Research Findings Confirm Link Between Communication and Safety

Research Findings Confirm Link Between Communication and Safety

Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills

Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills

Congratulations to ONS Director-at-Large Valerie Burger, RN, MA, MS, OCN®, CPN, whom the ONS Board of Directors selected as treasurer, and ONS Director-at-Large Darcy Burbage, DNP, RN, AOCN®, CBCN®, whom it selected as secretary, during its April 13, 2021, meeting.

ONS board of directors

Board Appoints Officers, Doubles Chapter Visits, Updates Navigator Position, and More

Nursing Considerations for Prostate Cancer Survivorship Care

Clinical practice

Nursing Considerations for Prostate Cancer Survivorship Care

Multimethod Approach Supports Providers’ Mental Health During COVID-19

Multimethod Approach Supports Providers’ Mental Health During COVID-19

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib (Truseltiq™), a kinase inhibitor for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. FDA also approved the FoundationOne® CDx as a companion diagnostic for infigratinib.

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma

Maximize Your Words’ Healing Power

Clinical practice

Maximize Your Words’ Healing Power

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras™), a RAS GTPase family inhibitor, for adult patients with KRAS G12Cmutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-Mutated NSCLC

On May 27, 2021, the U.S. Food and Drug Administration (FDA) approved piflufolastat F 18 (Pylarify®), a drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.

U.S. Food and Drug Administration (FDA)

FDA Approves Second PSMA-Targeted PET Imaging Drug for Prostate Cancer

ONS Center for Innovation Launches New Tool to Improve Nurses' Professional Development

ONS Center for Innovation Launches New Tool to Improve Nurses' Professional Development

Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer

Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer

Survey Results Support Predicted Effects of Pandemic Screening Drop

Cancer screening

Survey Results Support Predicted Effects of Pandemic Screening Drop

Oncology Drug Reference Sheet: Trilaciclib

Clinical practice

Oncology Drug Reference Sheet: Trilaciclib

Find Your Voice With ONS’s Leadership Development Committee

Find Your Voice With ONS’s Leadership Development Committee

FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC

What the Evidence Says For Dance/Movement Therapy in Cancer Care

Clinical practice

What the Evidence Says About Dance/Movement Therapy in Cancer Care

FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer

U.S. Food and Drug Administration (FDA)

FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer

Text Messaging Reduces Disparities in Colorectal Cancer Screening

Text Messaging Reduces Disparities in Colorectal Cancer Screening

The Case of the Weight Loss Wishes

Clinical practice

The Case of the Weight Loss Wishes

Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer

Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer

Back to Top ▲